Valneva SE (“Valneva”), a leading pure-play vaccines biotech company, today reports its consolidated financial results for the first quarter ended March 31, 2015 and provides an operational update. The condensed consolidated interim financial report is available on the Company’s website www.valneva.com. It includes the preliminary first-time consolidation of Crucell Sweden AB (now Valneva Sweden AB) and acquired assets related to DUKORAL® and the Nordics vaccine distribution business.
Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud, President and Chief Business Officer of Valneva, commented, “We are pleased to present a quarter showing our operational business, including the integration of the newly acquired DUKORAL® and Nordics vaccine distribution business, performed to our expectations. We will remain focused on executing our strategy to build a leading, financially self-sustainable pure-play vaccine company balancing growth from commercial product contributions and investments in promising R&D vaccine programs.”
Valneva Reports Strong Q1 2015 Financial Results and Provides Operational Update
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.